Health Insurance Implications – Coronavirus Disease (COVID-19) Sector Impact – June 2020

2020-06-18
Price :
Published : Jun-2020
No. of Pages : 61

Health Insurance Implications – Coronavirus Disease (COVID-19) Sector Impact – June 2020

Summary

The highly contagious coronavirus (SARS-CoV-2), dubbed COVID-19 (formerly 2019-nCoV), which emerged at the close of 2019, has led to a medical emergency across the world, with the World Health Organization (WHO) officially declaring the novel coronavirus a pandemic on March 11, 2020.

The virus is also having a growing impact on the global economy including the health insurance industry. This report reflects how government bodies and healthcare authorities are reacting to protect policyholder interest and minimize the impact on the health insurance industry during the COVID-19 crisis.

Key Highlights

– A number of reports estimated the impact of COVID-19 on unemployment rates and loss of ESI. It was highlighted that a high proportion of people who lose ESI coverage will be eligible for ACA coverage. However, almost twice as many people in states that did not expand Medicaid coverage with ACA will remain uninsured compared to expansion states.
– In the US, payers reported surges in the demand for telehealth services since the pandemic began, with some even announcing that these services will now be made permanent. In addition, lawmakers from some states have asked the government to make temporary changes to telehealth regulations permanent after the crisis has abated.
– Payers in many regions have revealed the impact of COVID-19 on the mental health of their members. In response, many have begun to provide them with access to platforms and apps, often free of charge. In addition, some payers in the US have waived costs to mental and behavioral health services for their members.

Scope

– This report reflects how government bodies and healthcare authorities are reacting to protect policyholder interest and minimize the impact on the health insurance industry during the COVID-19 crisis.
– Regions covered in this report include the US, Canada, Europe, APAC, the Middle East and Africa, and South and Central America.
– This report will be updated every month.

Reasons to Buy

– See how government bodies and healthcare authorities around the world are reacting to protect policyholder interest and minimize the impact on the health insurance industry during the COVID-19 crisis.

Filed in: Pharmaceutical
Publisher : GlobalData
More Reports
Title Price Buy Now

Radiation Dose Management Market by Products & Services (Standalone Solutions, Integrated Solutions, Services), Modality (Computed Tomography, Nuclear Medicine), Application (Oncology, Cardiology, Orthopedic), End User (Hospitals) – Global Forecast to 2025

“Radiation dose management market is projected to grow at CAGR of 13.9% from 2020 to 2025” The global radiation dose management market is projected to reach USD 422.65 million by 2025 from USD 220.22 million in 2020, at a CAGR of 13.9% from 2020 to 2025. Growth in this market is driven by the increasing use of medical imaging modalities due to the rising incidence of chronic diseases, increasing concerns over radiation dose exposure, growth in the installed base of radiology equipment, and growing awareness on radiation dose management. On the other hand, the lack of standardized procedures and dose protocols for radiation dose management for healthcare organizations is a major market challenge. “Radiation dose management solutions segment to witness the highest growth during t......
$4950

Coronavirus Disease 2019 (COVID-19) – Pipeline and Clinical Trial Analysis – June 2020

Coronavirus Disease 2019 (COVID-19) - Pipeline and Clinical Trial Analysis - June 2020 Summary The biopharmaceutical industry has risen to meet the challenge posed by this novel virus: hundreds of companies across the globe have entered the race to develop a treatment and a preventive vaccine. While the industry has shown its mettle by immediately initiating research on agents for COVID-19, the progress of R&D in general has been adversely impacted, with delays in clinical trial timelines and regulatory decisions across disease areas. Over the coming months, as trial data readouts become available, frontrunners will emerge in both the therapeutic and preventive categories. Currently, the therapeutics space is dominated by candidates already approved for other disease indications; one of......
$2495

Coronavirus Disease 2019 (COVID-19) – Analysis of the Emerging Disease Landscape – June 2020

Coronavirus Disease 2019 (COVID-19) - Analysis of the Emerging Disease Landscape - June 2020 Summary The Epidemiology of COVID-19 is rapidly evolving and a number of companies have begun to invest in this space. The absence of proven therapeutic options and the lack of a vaccine to protect against infection has led to a race to develop effective interventions. A range of players - from pharma and biotech firms to academic institutions and government agencies - have thrown their hats in the ring. Scope - Global epidemiology metrics and trends - Snapshot of epidemiological trends to date in the top three most-affected countries - An overview of the pipeline for antivirals and vaccines - Summary of available efficacy data - An assessment of the clinical trials landscape by phase, sponsor ......
$2495

Contract Manufacturing Service Agreements – Rising Manufacturing Opportunities Driven by Pharmaceutical Pipeline Expansion

Contract Manufacturing Service Agreements - Rising Manufacturing Opportunities Driven by Pharmaceutical Pipeline Expansion Summary This report is a brand new publication covering contract service agreements, across a range of different services and manufacturing scales. The number of contract service agreements secured serves as a primary indicator of a CMO's performance. Contract Manufacturing Service Agreements is critical for establishing an understanding of the overall CMO industry, the range of services provided and the features of some of the largest CMOs participating in the industry. This report gives an important expert quantitative analysis on the contract manufacturing industry. Findings are based on the industry's most comprehensive databases of the CMO industry (GlobalData'......
$4995

COVID-19 Pipeline of Small and Mid-Cap Bio/Pharma Companies – Coronavirus Disease 2019 Sector Forecast

COVID-19 Pipeline of Small and Mid-Cap Bio/Pharma Companies - Coronavirus Disease 2019 Sector Forecast Summary The Coronavirus (COVID-19) company impact report analyses how the pandemic has impact Small and Mid Bio/Pharma Companies. Scope - This PowerPoint based report gives an important expert analysis on how the developement of vaccines and therapeutics for COVID-19 has been approached by Small and Mid Cap Bio/Pharma Companies. - Findings are based on the industry's most comprehensive platform the Pharma Intelligence Center, including Deals, News, Drugs, Sales, Clinical Trials database and recent analysis. Reasons to Buy - An overview of how Small and Mid Cap Bio/Pharma Companies have approached the developemnt of vaccines and therapeutics for the COVID-19 pandemic.......
$695

COVID-19 Impact on Inovio Pharmaceuticals Inc.

COVID-19 Impact on Inovio Pharmaceuticals Inc. Summary This PowerPoint based report gives an important expert analysis on how COVID-19 will affect Inovio Pharmaceuticals Inc. Findings are based on the industry's most comprehensive platform the Pharma Intelligence Center, including Deals, News, Drugs, Sales, Clinical Trials database and recent analysis. Scope - The coronavirus (COVID-19) company impact report analyses how the pandemic will impact Inovio Pharmaceuticals Inc. performance. Inovio's focus is on DNA-based vaccines requiring a novel route of administration - Inovio's pipeline is most active in early-stage drug development - INO-4800 is Inovio's COVID-19 vaccine - Funding from different sources for INO-4800 Reasons to Buy - An overview of how Inovio Pharmaceuticals Inc. will......
$495

Hepatitis B Tests (In Vitro Diagnostics) – Global Market Analysis and Forecast Model (COVID-19 market impact)

Hepatitis B Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 market impact) Summary Hepatitis B Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 market impact) is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area. The model discusses in detail the impact of COVID-19 on Hepatitis B Tests market for the year 2020 and beyond. Hepatitis B is a common cause of liver disease across the globe, and remains a major issue for most of the governments despite the fact that an effective vaccine has been available since 1982. The World Health Organization (WHO) recommends that all infants receive the hepatitis B vaccination and universal vaccinations have now been implemented in numerous count......
$7500

Hepatitis C Tests (In Vitro Diagnostics) – Global Market Analysis and Forecast Model (COVID-19 market impact)

Hepatitis C Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 market impact) Summary Hepatitis C Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 market impact) is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area. The model discusses in detail the impact of COVID-19 on Hepatitis C Tests market for the year 2020 and beyond. Hepatitis C is a viral infection caused by hepatitis C virus (HCV). Hepatitis C virus is a blood borne virus that causes liver disease and can cause acute and chronic hepatitis. Infection may be caused through injection drug use, transfusion of unscreened blood products, unsafe injection practices, sexual contact and from infected mother to her baby. Diagnosis......
$7500

HIV Tests (In Vitro Diagnostics) – Global Market Analysis and Forecast Model (COVID-19 market impact)

HIV Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 market impact) Summary HIV Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 market impact) is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area. The model discusses in detail the impact of COVID-19 on HIV Tests market for the year 2020 and beyond. HIV is an ongoing, global public health issue that remains a major priority for most governments. HIV tests are performed for two purposes: i) screening and diagnosis; or ii) monitoring of HIV-positive patients, particularly those undergoing antiretroviral therapy (ART). Screening of pregnant women for HIV is standard of care in most countries and considered to be a cost-effective st......
$7500

South Korea Healthcare, Regulatory and Reimbursement Landscape – CountryFocus

South Korea Healthcare, Regulatory and Reimbursement Landscape - CountryFocus Summary GlobalData, the industry analysis specialist, has released its latest report, "South Korea Healthcare, Regulatory and Reimbursement Landscape - CountryFocus". The report is an essential source of information on analysis of the healthcare, regulatory and reimbursement landscape in South Korea. It identifies the key trends in the country's healthcare market and provides insights into its demographic, regulatory, and reimbursement landscape and healthcare infrastructure. Most importantly, the report provides valuable insights into the trends and segmentation of its pharmaceutical and medical device markets. It uses data and information sourced from proprietary databases, secondary research, and in-house an......
$1995
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy